The Hamner Institutes for Health Sciences has reached a research agreement with Hepregen Corporation, a Massachusetts company that focuses on liver research technologies.
Privately-held Hepregen has developed what it calls “liver-in-a-dish” technology with products HepatoPac and HepatoMune. The partnership with The Hamner will focus on research and development efforts aimed at defining basic concepts for the potential for new micro-liver products. The partners will also research new applications for Hepregen’s existing micro-liver products that are already in use in drug development.
The Hamner has extensive experience working on drug and chemical safety in partnership with universities, companies and the government. No financial terms of the partnership were disclosed.
The research effort will be led by Dr. Edward LeCluyse, associate investigator at The Hamner, and Dr. Michael Holsapple, newly appointed vice president of Toxicology Product Development at Hepregen, along with Jack McGeehan, Hepregen’s vice president of operations.
“This research partnership provides yet another example of The Hamner’s ability to attract and partner with high quality commercial enterprises that share our organization’s commitment to advancing human health,” William Greenlee, president and CEO of The Hamner, said in a statement. “We look forward to working with Hepregen in our mutual quest to provide advanced, next generation predictive health tools to the pharmaceutical, chemical and related industries.”
